One hundred and ninety-four patient episodes were audited for response to a standardised 1 g intravenous iron infusion for medical outpatients with iron deficiency anaemia. Patients received either ferric carboxymaltose or iron polymaltose. At 5-7 weeks after infusion, mean increase in Hb was 26.7 g/L and ferritin was 161 mcg/L, and only one patient had Hb <100 g/L. This reassures that 1 g dose of intravenous iron is sufficient for most patients, with benefits for treatment costs and patient convenience.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imj.15110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical Development of Magnetic Nanoparticles for Hyperthermia Treatment of Pancreatic Cancer.
ACS Appl Mater Interfaces
January 2025
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT), Vall d'Hebron Institute of Research (VHIR), 08035 Barcelona, Spain.
Pancreatic ductal adenocarcinoma (PDAC) is a very challenging disease with a very poor prognosis. It is characterized by a dense desmoplastic stroma that hampers drug penetration and limits the effectiveness of conventional chemotherapy (CT). As an alternative, the combination of CT with hyperthermia (HT) has been proposed as an innovative treatment modality for PDAC.
View Article and Find Full Text PDFA methotrexate labelled dual metal oxide nanocomposite for long-lasting anti-cancer theranostics.
Mater Today Bio
February 2025
Queensland Micro- and Nanotechnology Centre, Griffith University, Nathan, Queensland, 4111, Australia.
We explored the feasibility of a self-assembled chitosan nanocomposite incorporating cerium oxide/nanoceria and superparamagnetic iron oxide nanoparticles (Chit-IOCO NPs), conjugated with methotrexate (MTX) and Cy5 dye, as an integrated cancer theranostic nanosystem (Chit-IOCO-MTX-Cy5). In this system, nanoceria serves as an anti-cancer agent, while the superparamagnetic iron oxide nanoparticles function as a negative contrast agent for MR imaging. This dual metal oxide nanocomposite is conjugated with MTX which is a structural analogue of folate, serving both as a targeting mechanism for folate receptors on cancer cells and as a chemotherapeutic drug.
View Article and Find Full Text PDFReprogramming Dysfunctional Dendritic Cells by a Versatile Catalytic Dual Oxide Antigen-Captured Nanosponge for Remotely Enhancing Lung Metastasis Immunotherapy.
ACS Nano
December 2024
Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 300044, Taiwan.
Dendritic cells (DCs) play a crucial role in initiating antitumor immune responses. However, in the tumor environment, dendritic cells often exhibit impaired antigen presentation and adopt an immunosuppressive phenotype, which hinders their function and reduces their ability to efficiently present antigens. Here, a dual catalytic oxide nanosponge (DON) doubling as a remotely boosted catalyst and an inducer of programming DCs to program immune therapy is reported.
View Article and Find Full Text PDFIron Deficiency Anemia as a Rare Presentation of Subacute Bacterial Endocarditis Caused by a Rare Organism.
Cureus
November 2024
General Internal Medicine, Luton and Dunstable University Hospital, Luton, GBR.
Infective endocarditis commonly presents with fever, malaise, fatigue, and chest pain. However, this case report details an atypical presentation of infective endocarditis when a 63-year-old male patient was referred by his general practitioner to the emergency department with shortness of breath and substantial weight loss to investigate his symptomatic anemia. His initial assessments revealed severe iron deficiency anemia without any gastrointestinal or any other source of bleeding.
View Article and Find Full Text PDFThe Efficacy and Safety of Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Diseases
December 2024
Department of Cardiology, Valley Medical Center, University of Washington, Seattle, WA 98055, USA.
Iron deficiency (ID) often coexists with heart failure (HF), and its prevalence increases with the severity of HF. Intravenous ferric carboxymaltose (FCM) has been associated with improvements in clinical outcomes, functional capacity, and quality of life (QoL) in patients with HF and ID. However, while earlier studies showed favorable results, more recent studies have failed to demonstrate significant improvements in outcomes for patients with heart failure with reduced ejection fraction (HFrEF) and ID.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!